« Back

Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th Annual Healthcare Conference

11/04/16 8:30 AM EDT

Webcast Accessible via Sarepta Therapeutics Website

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2016-- Sarepta Therapeutics (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, announced today that it is scheduled to present at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale, Arizona on Monday, November 7, 2016 at 5:30 PM, Eastern Time. Edward Kaye, Sarepta's chief executive officer, will be the presenter at the fireside chat.

The presentation will be webcast live on the investor relations section of the Sarepta Therapeutics website at www.sarepta.com and will be archived under the events and presentations section following the presentation for 90 days. Please connect to Sarepta’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates. For more information, please visit us at www.sarepta.com.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Brian Reid, 212-257-6725
breid@w2ogroup.com


 

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.